Novartis divestment on hold
This article was originally published in The Tan Sheet
Executive Summary
Swiss company will reorganize its Health Food & Slimming and Sports Nutrition businesses into stand-alone unit called Nutrition et Santé, postponing sale of two divisions "due to a lack of attractive offers," firm says Nov. 29. Company hopes reorganization will build value while Novartis seeks appropriate buyer. "We will pursue our strategy, but until now the offers have not matched the value of the brand portfolio," firm says. Novartis announced divestiture plans in February and subsequently sold Food & Beverage segment in October (1"The Tan Sheet" Oct.14, 2002, In Brief). Current Health & Functional Foods head Alain Chatillon will serve as Nutrition et Santé CEO...
You may also be interested in...
Ovaltine sale overseas
UK-based Associated British Foods picks up rights to malt-based product line worldwide, except for U.S. and Puerto Rico, with acquisition of Novartis' Food & Beverage business for about $267.5 mil. ($1=€1.02), firms announce Oct. 8. Himmel Nutrition has held U.S. licensing rights to Ovaltine since 1992, according to Novartis. Divested F&B business generated approximately $239.5 mil. in 2001 sales, constituting 43% of Health & Functional Food division's revenue; Novartis announced plans to divest the division in February (1"The Tan Sheet" Feb. 11, 2002, p. 12). Negotiations to sell other H&FF businesses, including Sports Nutrition division, "are proceeding," firm says. Benefiber, Resource Wellness supplement lines are housed in Novartis' Medical Nutrition unit, which is not for sale...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.